Amyotrophic lateral sclerosis: A long preclinical period?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1232-1238

  Eisen, Andrew ^a   Kiernan, Matthew ^b   Mitsumoto, Hiroshi ^c   Swash, Michael ^d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEUROLOGICAL INSTITUTE   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; DISEASE MODEL; HUMAN; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRODROMAL SYMPTOM; RISK FACTOR; SYNAPTIC TRANSMISSION; TIME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; PRODROMAL SYMPTOMS; RISK FACTORS; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 84896103939     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-307135     Document Type: Review

References (105)

1. van Zundert B, Izaurieta P, Fritz E, et al. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Cell Biochem 2012;113:3301-12.
2. Allain AE, Le Corronc H, Delpy A, et al. Maturation of the GABAergic transmission in normal and pathologic motoneurons. Neural Plast 2011;2011:905624.
3. Morreall J, Petrova L, Doetsch PW. Transcriptional mutagenesis and its potential roles in the etiology of cancer and bacterial antibiotic resistance. J Cell Physiol 2013;228:2257-61.
4. Omidvarnia A, Fransson P, Metsaranta M, et al. Functional bimodality in the brain networks of preterm and term human newborns. Cereb Cortex 2013; [Epub ahead of print].
5. Ben-Ari Y. GABA excites and sculpts immature neurons well before delivery: modulation by GABA of the development of ventricular progenitor cells. Epilepsy Curr 2007;7:167-9.
6. El-Ansary A, Al-Ayadhi L. Neuroin flammation in autism spectrum disorders. J Neuroinflammation 2012;9:265.
7. Graeber MB, Li W, Rodriguez ML. Role of microglia in CNS inflammation. FEBS Lett 2011;585:3798-805.
8. Caselli RJ, Locke DE, Dueck AC, et al. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement 2014;10:84-92.
9. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis 2013;33(Suppl 1):S405-16.
10. Tadaiesky MT, Dombrowski PA, Figueiredo CP, et al. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008;156:830-40.
11. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437-44.
12. Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat Disord 2009;15:457-60.
13. Schneider F, Althaus A, Backes V, et al. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 5):55-9.
14. Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms: identification and management. Parkinsonism Relat Disord 2007;13(Suppl 3):S450-6.
15. Panyakaew P, Bhidayasiri R. The spectrum of preclinical gait disorders in early Parkinson's disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking. J Neural Transm 2013;120:1665-72.
16. Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning. Neuroscientist 2009;15:28-35.
17. Eisen A. The real onset of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:593.
18. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732-9.
19. Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 1988;51:165-8.
20. de Carvalho M, Swash M. The onset of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2006;77:388-9.
21. Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002;73:199-201.
22. de Carvalho M, Dengler R, Eisen A, et al. The Awaji criteria for diagnosis of ALS. Muscle Nerve 2011;44:456-7.
23. Vucic S, Ziemann U, Eisen A, et al. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry 2013;84:1161-70.
24. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-4.
25. Brown RH Jr., Robberecht W. Amyotrophic lateral sclerosis: pathogenesis. Semin Neurol 2001;21:131-9.
26. Martin E, Cazenave W, Cattaert D, et al. Embryonic alteration of motoneuronal morphology induces hyperexcitability in the mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2013;54:116-26.
27. Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav 2013;3:431-57.
28. Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav 2013;3:335-50.
29. Ozdinler PH, Benn S, Yamamoto TH, et al. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G(9)(3)A transgenic ALS mice. J Neurosci 2011;31:4166-77.
30. Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007;10:608-14.
31. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011;29:824-8.
32. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009;187:761-72.
33. Quinlan KA. Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis. Integr Comp Biol 2011;51:913-25.
34. Quinlan KA, Schuster JE, Fu R, et al. Altered postnatal maturation of electrical properties in spinal motoneurons in a mouse model of amyotrophic lateral sclerosis. J Physiol 2011;589:2245-60.
35. van Zundert B, Peuscher MH, Hynynen M, et al. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci 2008;28:10864-74.
36. Frank SA. Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci USA 2010;107(Suppl 1):1725-30.
37. Ince PG, Highley JR, Kirby J, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011;122:657-71.
38. Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Curr Opin Neurol 2012;25:530-5.
39. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013;14:248-64.
40. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12:310-22.
41. Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012;124:339-52.
42. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617-28.
43. Factor-Litvak P, Al-Chalabi A, Ascherio A, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14(Suppl 1):33-43.
44. Talbot K. Familial versus sporadic amyotrophic lateral sclerosis - a false dichotomy? Brain 2011;134:3429-31.
45. Ganu RS, Harris RA, Collins K, et al. Early origins of adult disease: approaches for investigating the programmable epigenome in humans, nonhuman primates, and rodents. ILAR J 2012;53:306-21.
46. Eisen A, Turner M. Does variation in neurodegenerative disease suscepibility and phenotype reflect cerebral differences at the network level? Amyotroph Lateral Scler Frontotemporal Degener 2013;14:487-93.
47. Rulten SL, Caldecott KW. DNA strand break repair and neurodegeneration. DNA Repair (Amst) 2013;12:558-67.
48. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci 1991;14:453-501.
49. Kennedy SR, Loeb LA, Herr AJ. Somatic mutations in aging, cancer and neurodegeneration. Mech Ageing Dev 2012;133:118-26.
50. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution 1957;11:398-411.
51. Lynch KE, Kemp DJ. Nature-via-nurture and unravelling causality in evolutionary genetics. Trends Ecol Evol 2014;29:2-4.
52. Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010;81:1324-6.
53. Huisman MH, de Jong SW, van Doormaal PT, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 2011;82:1165-70.
54. Neilson S, Robinson I. Reinterpreting mortality statistics: some uses of Gompertzian analysis in epidemiological research. J Clin Epidemiol 1993;46:1063-9.
55. Chio A, Magnani C, Schiffer D. Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957-1987; application to birth cohorts. Neuroepidemiology 1995;14:269-77.
56. Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009;65:378-85.
57. Weisskopf MG, Gallo V, O'Reilly EJ, et al. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2010;74:1927-8.
58. Trojsi F, Monsurro MR, Tedeschi G. Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: state of the art and research perspectives. Int J Mol Sci 2013;14:15286-311.
59. D'Amico E, Factor-Litvak P, Santella RM, et al. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 2013;65C:509-27.
60. Chen M, Zhang L. Epigenetic mechanisms in developmental programming of adult disease. Drug Discov Today 2011;16:1007-18.
61. Marques SC, Oliveira CR, Pereira CM, et al. Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:348-55.
62. Qureshi IA, Mehler MF. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr Neurol Neurosci Rep 2011;11:464-73.
63. Wilson ME, Sengoku T. Developmental regulation of neuronal genes by DNA methylation: Environmental influences. Int J Dev Neurosci 2013;31:448-51.
64. Alagiakrishnan K, Gill SS, Fagarasanu A. Genetics and epigenetics of Alzheimer's disease. Postgrad Med J 2012;88:522-9.
65. Marques S, Outeiro TF. Epigenetics in Parkinson's and Alzheimer's diseases. Subcell Biochem 2012;61:507-25.
66. van Heesbeen HJ, Mesman S, Veenvliet JV, et al. Epigenetic mechanisms in the development and maintenance of dopaminergic neurons. Development 2013;140:1159-69.
67. Figueroa-Romero C, Hur J, Bender DE, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS ONE 2012;7:e52672.
68. Chestnut BA, Chang Q, Price A, et al. Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 2011;31:16619-36.
69. Bae JS, Simon NG, Menon P, et al. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol 2013;9:65-74.
70. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
71. Kiernan MC, Petri S. Hyperexcitability and amyotrophic lateral sclerosis. Neurology 2012;78:1544-5.
72. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-9.
73. Delestree N, Manuel M, Iglesias C, et al. Adult spinal motoneurones are not hyperexcitable in a mouse model of inherited amyotrophic lateral sclerosis. J Physiol 2014; (Epub ahead of print).
74. Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2012;13:245-50.
75. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 1993;86:55-64.
76. Maekawa S, Al-Sarraj S, Kibble M, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain 2004;127:1237-51.
77. Foerster BR, Callaghan BC, Petrou M, et al. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology 2012;78:1596-600.
78. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540-50.
79. Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129:2436-46.
80. Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 2005;128:1323-9.
81. Gonzalez-Burgos G, Fish KN, Lewis DA. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast 2011;2011:723184.
82. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005;6:312-24.
83. Ramirez-Jarquin UN, Lazo-Gomez R, Tovar YRLB, et al. Spinal inhibitory circuits and their role in motor neuron degeneration. Neuropharmacology 2013; (Epub ahead of print).
84. Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2012;83:659-62.
85. De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious agents and neurodegeneration. Mol Neurobiol 2012;46:614-38.
86. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012;71:444-57.
87. Shastri A, Bonifati DM, Kishore U. Innate immunity and neuroinflammation. Mediators Inflamm 2013;2013:342931.
88. Cunningham C. Microglia and neurodegeneration: The role of systemic inflammation. Glia 2013;61:71-90.
89. Harry GJ. Microglia during development and aging. Pharmacol Ther 2013.
90. Provencal N, Suderman MJ, Vitaro F, et al. Childhood chronic physical aggression associates with adult cytokine levels in plasma. PLoS One 2013;8:e69481.
91. Vivekananda U, Manjalay ZR, Ganesalingam J, et al. Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. J Neurol Neurosurg Psychiatry 2011;82:635-7.
92. Knott AB, Perkins G, Schwarzenbacher R, et al. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 2008;9:505-18.
93. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med 2008;10:291-315.
94. Martin LJ. Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci 2012;107:355-415.
95. Lagouge M, Larsson NG. The role of mitochondrial DNA mutations and free radicals in disease and ageing. J Intern Med 2013;273:529-43.
96. Knott AB, Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann N Y Acad Sci 2008;1147:283-92.
97. Song W, Song Y, Kincaid B, et al. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1alpha. Neurobiol Dis 2013;51:72-81.
98. Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 2012;13:659-71.
99. Chinnery PF, Elliott HR, Hudson G, et al. Epigenetics, epidemiology and mitochondrial DNA diseases. Int J Epidemiol 2012;41:177-87.
100. Chaturvedi RK, Flint Beal M. Mitochondrial Diseases of the Brain. Free Radic Biol Med 2013;63C:1-29.
101. Goodall EF, Heath PR, Bandmann O, et al. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci 2013;7:178.
102. Benatar M, Polak M, Kaplan S, et al. Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J Neurol Sci 2006;251:3-9.
103. Ng MC, Ho JT, Ho SL, et al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 2008;27:8-13.
104. Corvol JC. Neuroprevention: a new challenge? Rev Neurol (Paris) 2012;168:796-801.
105. Lai MC, Lombardo MV, Suckling J, et al. Biological sex affects the neurobiology of autism. Brain 2013;136:2799-815.